After eating a fatty meal, people who took this supplement had lower levels of fat in their blood than those who took a placebo, suggesting it helps the body clear fat from the bloodstream faster.
Scientific Claim
Twelve weeks of supplementation with 282 mg/day epigallocatechin-3-gallate and 80 mg/day resveratrol attenuates the postprandial rise in plasma triacylglycerol during a high-fat mixed meal test in overweight and obese adults, compared to placebo.
Original Statement
“Furthermore, EGCG+RES supplementation attenuated the increase in plasma triacylglycerol concentrations during the HFMM test that was observed after placebo (P-time × treatment = 0.04, P-placebo = 0.01).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
probability
Can suggest probability/likelihood
Assessment Explanation
RCT design supports causation, but abstract lacks details on triglyceride measurement timing or confounder control. 'Attenuated' is accurate but should be qualified as 'likely attenuated' due to limited data.
More Accurate Statement
“Twelve weeks of supplementation with 282 mg/day epigallocatechin-3-gallate and 80 mg/day resveratrol likely attenuates the postprandial rise in plasma triacylglycerol during a high-fat mixed meal test in overweight and obese adults, compared to placebo.”
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aWhether EGCG+RES consistently reduces postprandial triglyceride spikes across populations and meal types.
Whether EGCG+RES consistently reduces postprandial triglyceride spikes across populations and meal types.
What This Would Prove
Whether EGCG+RES consistently reduces postprandial triglyceride spikes across populations and meal types.
Ideal Study Design
A meta-analysis of ≥6 RCTs (n≥100 per trial) in overweight/obese adults comparing EGCG+RES (282+80 mg/d) vs placebo for ≥8 weeks, with primary outcome: postprandial triglyceride area under the curve (AUC) after standardized HFMM.
Limitation: Cannot determine if reduced triglycerides translate to reduced cardiovascular events.
Randomized Controlled TrialLevel 1bIn EvidenceCausal effect of EGCG+RES on postprandial triglyceride metabolism.
Causal effect of EGCG+RES on postprandial triglyceride metabolism.
What This Would Prove
Causal effect of EGCG+RES on postprandial triglyceride metabolism.
Ideal Study Design
A double-blind RCT with 150 overweight/obese adults (BMI 27–35, aged 30–60) randomized to EGCG+RES or placebo for 12 weeks, with primary endpoint: postprandial triglyceride AUC over 6 hours after a standardized HFMM, measured at 0, 1, 2, 4, and 6 hours.
Limitation: Does not assess long-term lipid profile changes or arterial health.
Prospective Cohort StudyLevel 2bWhether reduced postprandial triglycerides from EGCG+RES predict lower risk of atherosclerosis or cardiovascular events.
Whether reduced postprandial triglycerides from EGCG+RES predict lower risk of atherosclerosis or cardiovascular events.
What This Would Prove
Whether reduced postprandial triglycerides from EGCG+RES predict lower risk of atherosclerosis or cardiovascular events.
Ideal Study Design
A 5-year prospective cohort of 400 obese adults taking EGCG+RES (282+80 mg/d) or not, with quarterly postprandial triglyceride AUC measurements and annual carotid intima-media thickness or coronary calcium scoring.
Limitation: Cannot prove causation due to confounding by diet, exercise, and medication use.
Animal Model StudyLevel 4Mechanisms by which EGCG+RES enhances postprandial triglyceride clearance (e.g., LPL activity, VLDL secretion).
Mechanisms by which EGCG+RES enhances postprandial triglyceride clearance (e.g., LPL activity, VLDL secretion).
What This Would Prove
Mechanisms by which EGCG+RES enhances postprandial triglyceride clearance (e.g., LPL activity, VLDL secretion).
Ideal Study Design
A study in high-fat diet-fed rats (n=40/group) treated with EGCG+RES (equivalent human dose) for 12 weeks, measuring postprandial triglyceride clearance rate, lipoprotein lipase activity in muscle and adipose tissue, and hepatic VLDL secretion.
Limitation: Rat lipid metabolism differs from humans; cannot predict clinical outcomes.
Evidence from Studies
Supporting (1)
This study gave overweight people the same supplements mentioned in the claim for 12 weeks and then fed them a fatty meal. The supplements helped keep their blood fat levels from spiking as much as they did in people who took a placebo — exactly what the claim says.